SGIOYライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (27 4月 2024 @ 04:59):

Shionogi & Co., Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan...

Stats
本日の出来高	89 694.00
平均出来高	48 780.00
時価総額	13.45B
EPS	$0 ( 2024-01-29 )
次の収益日	( $0 ) 2024-05-08
Last Dividend	$0.121 ( 2021-09-28 )
Next Dividend	$0 ( N/A )
P/E	13.71
ATR14	$0.0260 (0.22%)

ボリューム相関

長: 0.13 (neutral)

短: 0.63 (weak)

Signal:(51.817) Neutral

Shionogi & Co., Ltd. 相関

10 最も正の相関

10 最も負の相関

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Shionogi & Co., Ltd. 相関 - 通貨/商品

0.76
( moderate )

0.73
( moderate )

0.00
( neutral )

0.72
( moderate )

-0.11
( neutral )

-0.76
( moderate negative )

Shionogi & Co., Ltd. 財務諸表

Annual	2023
収益:	$426.68B
総利益:	$356.58B (83.57 %)
EPS:	$621.31

FY	2023
収益:	$426.68B
総利益:	$356.58B (83.57 %)
EPS:	$621.31

FY	2022
収益:	$335.14B
総利益:	$272.41B (81.28 %)
EPS:	$378.75

FY	2021
収益:	$297.18B
総利益:	$244.65B (82.33 %)
EPS:	$91.26

Financial Reports:

No articles found.

Shionogi & Co., Ltd. Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Shionogi & Co., Ltd. Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 5.97 - Stable (19.35%)

Information

First Dividend	$0.124	2021-03-29
Last Dividend	$0.121	2021-09-28
Next Dividend	$0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	2	--
Total Paid Out	$0.245	--
Avg. Dividend % Per Year	0.00%	--
Score	3.75	--
Div. Sustainability Score	10.00
Div.Growth Potential Score	5.97
Div. Directional Score	9.09	--

Next Divdend (Est)
(2024-06-21)

$0 Estimate 0.00 %

Dividend Stability

0.04 Very Bad

Dividend Score

3.75

Pay Frequency

Semi-Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for OTC

Symbol	Title	Last dividend	Frequency	Yearly Dividend
TRBK	Ex Dividend Junior	2023-08-03	Semi-Annually	0.00%
ITJTY	Ex Dividend Junior	2023-10-31	Annually	0.00%
BKKPF	Ex Dividend Junior	2023-09-06	Annually	0.00%
PUODY	Ex Dividend Knight	2023-06-21	Annually	0.00%
EPOKY	Ex Dividend Knight	2023-10-23	Semi-Annually	0.00%
VDMCY	Ex Dividend Knight	2023-06-22	Semi-Annually	0.00%
KSBI	Ex Dividend Knight	2023-07-28	Quarterly	0.00%
CGEMY	Ex Dividend Knight	2023-05-25	Annually	0.00%
SCGLY	Ex Dividend Junior	2023-05-25	Annually	0.00%
FSUGY	Ex Dividend Knight	2023-09-07	Semi-Annually	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.363	1.500	2.73	4.10	[0 - 0.5]
returnOnAssetsTTM	0.114	1.200	6.21	7.46	[0 - 0.3]
returnOnEquityTTM	0.132	1.500	9.64	10.00	[0.1 - 1]
payoutRatioTTM	0.288	-1.000	7.12	-7.12	[0 - 1]
currentRatioTTM	6.57	0.800	10.00	8.00	[1 - 3]
quickRatioTTM	5.74	0.800	10.00	8.00	[0.8 - 2.5]
cashRatioTTM	2.47	1.500	10.00	10.00	[0.2 - 2]
debtRatioTTM	0.00724	-1.500	9.88	-10.00	[0 - 0.6]
interestCoverageTTM	16.34	1.000	5.06	5.06	[3 - 30]
operatingCashFlowPerShareTTM	445.43	2.00	10.00	10.00	[0 - 30]
freeCashFlowPerShareTTM	362.35	2.00	10.00	10.00	[0 - 20]
debtEquityRatioTTM	0.00826	-1.500	9.97	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.851	1.000	10.00	10.00	[0.2 - 0.8]
operatingProfitMarginTTM	0.383	1.000	4.35	4.35	[0.1 - 0.6]
cashFlowToDebtRatioTTM	13.06	1.000	10.00	10.00	[0.2 - 2]
assetTurnoverTTM	0.313	0.800	-1.249	-0.999	[0.5 - 2]
Total Score				12.21

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	3.45	1.000	9.75	0	[1 - 100]
returnOnEquityTTM	0.132	2.50	9.77	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	362.35	2.00	10.00	10.00	[0 - 30]
dividendYielPercentageTTM	0.00466	1.500	9.88	0	[0 - 0.4]
operatingCashFlowPerShareTTM	445.43	2.00	10.00	10.00	[0 - 30]
payoutRatioTTM	0.288	1.500	7.12	-7.12	[0 - 1]
pegRatioTTM	-0.00223	1.500	-3.35	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.302	1.000	4.94	0	[0.1 - 0.5]
Total Score				5.97

Shionogi & Co., Ltd.

Shionogi & Co., Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan. It offers Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment; Xofluza, an influenza virus drug; and Tivicay for HIV treatment. It also develops Symproic for opioid-induced constipation treatment; S-120083 for Inflammatory pain; S-010887 for Neuropathic pain; S-117957 for Insomnia; sivopixant for Neuropathic pain, Sleep Apnea Syndrome, and Refractory/unexplainedchronic cough; S-637880 for Neuropathic Low Back Pain; Zuranolone for Depression; SDT-001 for attention-deficit/hyperactivity disorder patients; BPN14770 for Fragile X syndrome and Alzheimer's disease; and S-237648 and S-309309 for Obesity. In addition, the company develops ADR-001 for Decompensated liver cirrhosis; S-723595 for NASH; S-588410 for Esophageal and Bladder cancer; S-488210 for Head and neck squamouscell carcinoma; S-588210 for Solid tumor; S-222611 for Malignant tumor; S-770108 for Idiopathic pulmonary fibrosis; SR-0379 for Cutaneous ulcer; S-005151 for Stroke and Epidermolysis bullosa; S-531011 for Solid tumor; S-0373 for Spinocerebellar ataxia; and S-600918 and S-217622 for COVID-19, as well as S-555739 for Control of the aggravation of COVID-19. Further, it offers antibody test kits for COVID-19. Shionogi & Co., Ltd. has collaboration agreements with Nagasaki University, the National Institute of Infectious Diseases, and The Kitasato University to develop antimalarial drugs. The company was formerly known as Shionogi Shoten Co., Ltd. and changed its name to Shionogi & Co., Ltd. in 1943. Shionogi & Co., Ltd. was founded in 1878 and is headquartered in Osaka, Japan.